-

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation at several upcoming investor conferences.

Details of each presentation are as follows:

Cowen 2nd Annual Genetic Medicines Summit
Panel: Gene Therapies - Clinical Topics
Date: Thursday, February 3, 2022
Time: 12:00 p.m. ET

SVB Leerink Global Healthcare Conference
Company Presentation
Date: Friday, February 18, 2022
Time: 3:40 p.m. ET

Cowen 42nd Annual Health Care Conference
Panel: Gene Therapy
Date: Wednesday March 9, 2022
Time: 12:50 p.m. ET

About Tenaya Therapeutics

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Contacts

Investors
Leone Patterson
Tenaya Therapeutics
IR@tenayathera.com

Media
Wendy Ryan
Ten Bridge Communications
Wendy@tenbridgecommunications.com

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Release Summary
Tenaya Therapeutics today announced participation at several upcoming investor conferences.
Release Versions
$Cashtags

Contacts

Investors
Leone Patterson
Tenaya Therapeutics
IR@tenayathera.com

Media
Wendy Ryan
Ten Bridge Communications
Wendy@tenbridgecommunications.com

Social Media Profiles
More News From Tenaya Therapeutics, Inc.

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center....

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present preclinical data at the European Society of Cardiology (ESC) Heart Failure 2022 conference....

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today provided business and program updates, and reported financial results for the first quarter ended March 31, 2022....
Back to Newsroom